Vertex Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
VRTX Vertex Pharmaceuticals Inc
CHPT ChargePoint Holdings Inc
BASMX iShares Total U.S. Stock Market Index Fund Investor A Shares
FLNT Fluent Inc
CCXI ChemoCentryx Inc
NVTA Invitae Corp
CLNE Clean Energy Fuels Corp
IMBBY Imperial Brands PLC
T AT&T Inc
JNJ Johnson & Johnson
Go

Health Care : Biotechnology | Large Cap Growth
Company profile

Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on developing medicines that treat the underlying cause of cystic fibrosis (CF) and it has several ongoing clinical and research programs to advance and extend treatment of CF. The Company's marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). Its four medicines are being used to treat the people with CF in North America, Europe and Australia. The Company has a pipeline of investigational therapies in other serious diseases where it is leveraging insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. The Company’s other pipeline products include CTX001, VX-147, VX-121, VX-561, VX-548, and VX-880.

Closing Price
$293.95
Day's Change
5.92 (2.06%)
Bid
--
Ask
--
B/A Size
--
Day's High
296.95
Day's Low
288.65
Volume
(Average)
Volume:
1,687,084

10-day average volume:
1,539,290
1,687,084

Company Profile

Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on developing medicines that treat the underlying cause of cystic fibrosis (CF) and it has several ongoing clinical and research programs to advance and extend treatment of CF. The Company's marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). Its four medicines are being used to treat the people with CF in North America, Europe and Australia. The Company has a pipeline of investigational therapies in other serious diseases where it is leveraging insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. The Company’s other pipeline products include CTX001, VX-147, VX-121, VX-561, VX-548, and VX-880.

Valuation Ratios

Price/Earnings (TTM)
23.29x
Price/Sales (TTM)
8.82x
Price/Book (MRQ)
6.18x
Price/Cash Flow (TTM)
29.64x
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

July 2022
Current Month
3.6M
Previous Month
3.2M
Percent of Float
1.41%
Days to Cover
2.2430 Days

Share Information

VRTX is in a share class of common stock
Float
254.9M
Shares Outstanding
255.8M
Institutions Holding Shares
1,587
92.24%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in millions.

Cash flow

Values displayed are in millions.

Company Officers

  • Jeffrey M. LeidenChmn.
  • Reshma KewalramaniPres.
  • Charles F. WagnerCFO
  • Stuart A. ArbuckleCOO
  • David AltshulerExec.VP

Address

Insider Trading

During the most recent quarter, 257K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.